Daniel J Keavy

6967196, Nov 22, 2005

Feb 22, 2000

09/890927

David W. Smith - Madison CT, US
Benito Munoz - San Diego CA, US
Kumar Srinivasan - Chicago IL, US
Carl P. Bergstrom - Madison CT, US
Prasad V. Chaturvedula - Cheshire CT, US
Milind S. Deshpande - Madison CT, US
Daniel J. Keavy - Killingworth CT, US
Wai Yu Lau - Meriden CT, US
Michael F. Parker - Higganum CT, US
Charles P. Sloan - Wallingford CT, US
Owen B. Wallace - Zionsville IN, US
Henry Hui Wang - Milford CT, US

Bristol-Myers Squibb Company - Princeton NJ
Merck & Co. Inc. - Rahway NJ

A61K031/407
A61K031/40
A61K031/54
A61K031/4965
A61K031/47

5142101, 514425, 5142275, 51425501, 514307, 514315, 51421712, 514278, 514412, 514428, 514357, 514331, 514408, 514602, 514365, 514381, 514406, 514359, 548565, 548229, 548470, 548546, 548566, 5483401, 548252, 5483751, 548255, 540362, 540609, 546 16, 546229, 546334, 546220

In accordance with the present invention, there is provided a novel class of sulfonamide compounds. Compounds of the invention contain a core sulfonamide group. Variable moieties connected to the sulfur atom and nitrogen atom of the sulfonamide group include substituted or unsubstituted hydrocarbyl moieties, substituted or unsubstituted heterocycle moieties, polycyclic moieties, halogen, alkoxy, ether, ester, amide, sulfonyl, sulfonamidyl, sulfide, carbamate, and the like. Invention compounds are capable of a wide variety of uses. For example sulfonamide compounds can act to modulate production of amyloid β protein and are useful in the prevention or treatment of a variety of diseases. Pharmaceutical compositions containing invention compounds are also provided. Such compositions have wide utility for the prevention or treatment of a variety of diseases.

56611854, Aug 26, 1997

Dec 14, 1995

8/572838

Katherine S. Takaki - Middletown CT
George N. Karageorge - Meriden CT
Daniel J. Keavy - Middletown CT
Michael F. Parker - Somers CT
Brett T. Watson - Wallingford CT

Bristol-Myers Squibb Co. - Princeton NJ

A61K 3117
C07C27506

514595

New melatonergic agents are phenyl alkanyl or phenyl alkyl substituted carboxamides and ureas of Formula I: ##STR1## wherein: R. sub. 1 =C. sub. 1-3 alkyl, allyl, C. sub. 3-6 cycloalkyl substituted C. sub. 1-4 alkyl; R. sub. 2 =hydrogen, halogen or C. sub. 1-4 alkoxy; R. sub. 3 =hydrogen or C. sub. 1-4 alkyl; R. sub. 4 =C. sub. 1-4 alkyl, C. sub. 1-4 alkyl substituted amino, carboxylic acid substituted C. sub. 1-4 alkyl or C. sub. 3-6 cycloalkyl, C. sub. 3-6 cycloalkyl, or straight or branched chain C. sub. 2-4 alkenyl; A=a linear C. sub. 2-4 alkanediyl or alkenediyl chain, provided that A not be --CH. sub. 2 CH. sub. 2 -- when X is a bond; and X=a covalent bond or oxygen.

59488174, Sep 7, 1999

Mar 4, 1998

9/034912

James Epperson - Cromwell CT
Graham Johnson - Madison CT
Daniel J. Keavy - Killingworth CT
Katherine S. Takaki - Middletown CT

Bristol-Myers Squibb Company - Princeton NJ

A61K 3134
A61K 31335
C07D30777
C07D31770

514463

Novel polycyclic ethyl alkylamides of formula I are active as melatonergic agents. ##STR1## wherein Z=CH (when a double bond is present) or (CH. sub. 2). sub. n, wherein n is 1-4; X=O, CH. sub. 2, or CH (when a double bond is present); R=C. sub. 1-6 alkyl, C. sub. 3-6 cycloalkyl, or C. sub. 1-3 haloalkyl, C. sub. 2-6 alkenyl, C. sub. 2-4 alkoxyalkyl, C. sub. 1-4 trifluoromethylalkyl, C. sub. 1-6 aminoalkyl; and Y=H, C. sub. 1-6 alkoxy or halogen.

55412289, Jul 30, 1996

Mar 8, 1995

8/376328

Katherine S Takaki - Middletown CT
George N. Karageorge - Meriden CT
Daniel J. Keavy - Middletown CT
Michael F. Parker - Somers CT
Brett T. Watson - Wallingford CT

Bristol-Myers Squibb Co. - Princeton NJ

A61K 3116
C07C23305

514630

New melatonergic agents are phenyl alkanyl or phenyl alkyl substituted carboxamides and ureas of Formula I: ##STR1## wherein: R. sub. 1 =C. sub. 1-3 alkyl, allyl, C. sub. 3-6 cycloalkyl substituted C. sub. 1-4 alkyl; R. sub. 2 =hydrogen, halogen or C. sub. 1-4 alkoxy; R. sub. 3 =hydrogen or C. sub. 1-4 alkyl; R. sub. 4 =C. sub. 1-4 alkyl, C. sub. 1-4 alkyl substituted amino, carboxylic acid substituted C. sub. 1-4 alkyl or C. sub. 3-6 cycloalkyl, C. sub. 3-6 cycloalkyl, or straight or branched chain C. sub. 2-4 alkenyl; A=a linear C. sub. 2-4 alkanediyl or alkenediyl chain, provided that A not be --CH. sub. 2 CH. sub. 2 -- when X is a bond; and X=a covalent bond or oxygen.

59815710, Nov 9, 1999

Oct 9, 1998

9/169784

John D. Catt - Southington CT
Graham Johnson - Madison CT
Daniel J. Keavy - Killingworth CT
Ronald J. Mattson - Meriden CT
Michael F. Parker - Middletown CT
Katherine S. Takaki - Middletown CT
Joseph P. Yevich - Southington CT

Bristol-Myers Squibb Company - Princeton NJ

C07D31760
C07D31908
A61K 3136
A61K 3135

514450

Novel derivatives of benzodioxa alkylene ethers are provided which are useful as melatonergic agents.

58890319, Mar 30, 1999

Feb 9, 1998

/020884

Daniel J. Keavy - Middletown CT
Michael F. Parker - Somers CT
Ronald J. Mattson - Meriden CT
Graham Johnson - Madison CT

Bristol-Myers Squibb Compnay - Princeton NJ

A61K 3144

514357

Certain N-acyl 2-aryl cyclopropylmethylamine derivatives are useful as melatonergic agents.

58565299, Jan 5, 1999

Dec 9, 1997

8/987478

John D. Catt - Southington CT
Graham Johnson - Madison CT
Daniel J. Keavy - Killingworth CT
Ronald J. Mattson - Meriden CT
Michael F. Parker - Middletown CT
Katherine S. Takaki - Middletown CT
Joseph P. Yevich - Southington CT

Bristol-Myers Squibb Company - Princeton NJ

C07D30879
C07D31916
C07D49302
C07D20904

549469

Novel derivatives of benzofuran and dihydrobenzofuran are provided which are useful as melatonergic agents.

55300120, Jun 25, 1996

Dec 22, 1994

8/362337

Ronald J. Mattson - Meriden CT
John D. Catt - Southington CT
Daniel J. Keavy - Middletown CT

Bristol-Myers Squibb Co. - Princeton NJ

A61K 31445
C07D21106

514330

Novel 3-alkoxybenzylpiperidines have melatonergic properties. They are believed useful in treating depression, jet-lag, work-shift syndrome, sleep disorders, glaucoma, some disorders associated with reproduction, cancer, immune disorders and neuroendocrine disorders.